Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Sometimes these things can be helpful, but it's of little relevance with respect to Algernon. These types of articles don't capture the value of the company accurately. The value (which is not noted in that article) is in the patents they have which protect the valuable asset (the drug which they have in hand and are scaling up).

Furthermore, these guys specifically did the BioPub releases to demonstrate the concept that they are skipping hundreds of millions of dollars worth of research costs by re purposing a safe drug with previous use in humans.

From a sheer business perspective, they are done diluting (they've said it themselves in BioPub articles) and they have cash in hand, and the only insider trading recently is BUYING by our CEO and Kal.

All good stuff IMO